Market Intelligence, Clinical Progress, and High-Purity Reagents for Oncology and Ribosomopathy Therapeutic Development.
TarMart Solution Ecosystem & Related Targets
"Comprehensive reagent toolkit for RPS27A drug discovery. Select your modality below:"
| Component / Network | Product Description | Product Link |
|---|---|---|
| Antigen | RPS27A Recombinant Protein High purity (>95%), Endotoxin <1EU/ug. Sequence Verified. Theoretical MW confirmed by MS. |
View RPS27A Products |
| Gene Delivery | RPS27A Promise-ORF / Lentivirus Full-length ORF for stable cell line construction and overexpression assays. |
View RPS27A Products |
| Benchmark Ab | Anti-RPS27A Recombinant Antibody Recombinant positive control for Western Blot, ELISA, and IHC. |
View RPS27A Products |
| Validator | RPS27A siRNA Set For target knockdown verification and phenotypic validation. |
View RPS27A Products |
| Related Target A | UBA52 Ubiquitin-Ribosomal Protein L40 Fusion. Crucial for comparative selectivity and target specificity screening. |
View UBA52 Products |
| Related Target B | MDM2 E3 ubiquitin-protein ligase downstream of ribosomal stress pathways. Essential for mechanism-of-action validation. |
View MDM2 Products |
| Critical Assay Challenge | The TarMart Advantage (Technical Spec) |
|---|---|
| Distinguishing free Ubiquitin from RPS27A fusion protein | Sequence Verified N-terminal and C-terminal specific constructs with precise mass spec validation |
| Off-target screening against other ribosomal proteins | High-purity homolog panel (including UBA52) strictly verified by SDS-PAGE and MS |
| Lack of Controls | Clinical Benchmark Antibodies (Biosimilars) and sequence-verified positive controls included |
| False Positives in Knockdown Assays | Validated siRNA sets included for precise target gene silencing verification |
Live RPS27A R&D Tracker
Market data changes daily. Access the latest global pipeline status directly:
Global Clinical Landscape & Future Outlook
The race for RPS27A therapeutics is intensifying, with major players shifting focus from traditional gene silencing to small-molecule inhibitors and PROTAC-mediated degradation. As first-generation therapies targeting ribosomal biogenesis reach the clinic, the next wave of R&D is targeting the specific ubiquitin-fusion cleavage mechanism of RPS27A to achieve tumor-selective apoptosis.
Competitive Modality & Indication Snapshot
| Modality | Representative Players | Key Indications | Critical Assay Need (Why TarMart?) |
|---|---|---|---|
| Small Molecule Inhibitors | Academic Medical Centers, Biotech Startups | Hematological Malignancies, Solid Tumors | Selectivity Assay (Need Mutant vs WT Proteins to verify binding pocket) |
| siRNA / ASO | RNAi Therapeutics Developers | Refractory Cancers | Target Knockdown Validation (Need sequence-verified siRNA and RT-qPCR controls) |
| PROTAC / Degraders | Targeted Protein Degradation Companies | Advanced Solid Tumors | Ubiquitination Kinetics (Need high-purity recombinant RPS27A as substrate) |